STOCK TITAN

ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options at $31.74

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ArriVent BioPharma, Inc. director John Hohneker received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share, expire on June 17, 2036, and vest on the first anniversary of the June 18, 2026 grant date, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider Hohneker John
Role null
Type Security Shares Price Value
Grant/Award Non-Qualified Stock Option (right to buy) 13,562 $0.00 --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 13,562 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 13,562 options Non-qualified stock option grant on June 18, 2026
Exercise price $31.74 per share Strike price for the non-qualified stock option
Underlying shares 13,562 shares Common stock covered by the option grant
Expiration date June 17, 2036 Option expiration for the granted award
Shares following transaction 13,562 options Total derivative securities held after the grant
Non-Qualified Stock Option financial
"security_title: "Non-Qualified Stock Option (right to buy)""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
exercise price financial
"conversion_or_exercise_price: "31.7400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-17T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: "Common Stock""
vesting financial
"The shares underlying this option vest on the first anniversary of the grant date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hohneker John

(Last)(First)(Middle)
C/O ARRIVENT BIOPHARMA, INC.
18 CAMPUS BOULEVARD SUITE 100

(Street)
NEWTOWN SQUARE PENNSYLVANIA 19073

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ArriVent BioPharma, Inc. [ AVBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$31.7406/18/2026A13,56206/18/2027(1)06/17/2036Common Stock13,562$0.0013,562D
Explanation of Responses:
1. The shares underlying this option vest on the first anniversary of the grant date, subject to the Reporting Person's continued service through the applicable vesting date.
By: /s/ James Kastenmayer, Attorney-in-Fact for: John Hohneker06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ArriVent BioPharma (AVBP) director John Hohneker report on this Form 4?

He reported receiving a grant of non-qualified stock options for 13,562 shares of common stock. These options are a form of equity compensation, giving him the right to buy shares at a fixed exercise price in the future if they vest.

How many ArriVent BioPharma (AVBP) options were granted to John Hohneker?

He was granted options on 13,562 shares of ArriVent BioPharma common stock. The filing shows this entire amount as held following the transaction, reflecting a new equity award rather than a purchase or sale in the open market.

What is the exercise price of John Hohneker’s ArriVent BioPharma (AVBP) options?

The options have an exercise price of $31.74 per share. This means he can choose to buy ArriVent BioPharma common stock at $31.74 for each optioned share once vested and before the options expire.

When do John Hohneker’s ArriVent BioPharma (AVBP) options vest?

The shares underlying this option vest on the first anniversary of the June 18, 2026 grant date. Vesting is conditioned on his continued service with the company through that vesting date, according to the footnote disclosure.

When do John Hohneker’s ArriVent BioPharma (AVBP) options expire?

These non-qualified stock options expire on June 17, 2036. If they are not exercised by that expiration date, they will lapse and no longer provide the right to buy ArriVent BioPharma common stock at the stated exercise price.

Is this ArriVent BioPharma (AVBP) Form 4 a buy or a sale of shares?

It reflects an acquisition of derivative securities through an option grant, not an open-market buy or sale. The transaction code is “A” for a grant or award, and no common shares were bought or sold in the market in this filing.